2026年11月14日,新版国家医保药品目录与商业健康保险创新药品目录在江苏苏州举行的2026创新药高质量发展大会现场正式发布 1。这是国家医保局成立以来开展的第九次国家基本医保药品目录调整 1。
此次调整后,基本医保目录共新增107种药品,其中包括51个1类创新药 1。目前,2026年版国家医保药品目录收录的药品总数达到3331个,其中西药1935个、中成药1396个 1。本轮目录调整覆盖了肿瘤、罕见病等多个临床急需领域 1。
在企业入选情况方面,默沙东共有22款产品被纳入国家医保药品目录,信达生物有17款药品被纳入医保 1。
On November 14, 2026, the new National Medical Insurance Drug Catalog and the Commercial Health Insurance Innovative Drug Catalog were officially released during the 2026 High-Quality Development Conference for Innovative Drugs held in Suzhou, Jiangsu Province 1. This event marked the ninth adjustment of the national basic medical insurance drug catalog since the establishment of the National Healthcare Security Administration 1.
The updated national medical insurance catalog includes a total of 3,331 drugs, comprising 1,935 Western medicines and 1,396 traditional Chinese patent medicines 1. Among the additions, 107 new drugs were incorporated into the basic insurance list, including 51 Class 1 innovative drugs 1. The adjustments focused on clinical urgent needs across various therapeutic areas, such as oncology and rare diseases 1.
Several pharmaceutical companies saw significant representation in the new list. Merck & Co. had 22 products included in the national medical insurance drug catalog, while Innovent Biologics secured coverage for 17 of its drugs 1.
评论
还没有评论,欢迎留下第一条。